Full Title
A Study of MB-CART2019.1 (zamtocabtagene autoleucel (zamto-cell)) Cells in People with Diffuse Large B-Cell LymphomaPurpose
CAR T-cell therapy is a type of immunotherapy used to treat some people with lymphoma that has continued to grow despite prior treatment. The treatment involves using a patient’s own T cells (a type of white blood cell), genetically modifying them in the laboratory to recognize a protein on cancer cells, and multiplying them. The modified T cells, known as CAR T cells, are then returned to the patient to find and kill cancer cells throughout the body.
In this study, researchers are evaluating a new type of CAR T-cell therapy called MB-CART2019.1 in people with diffuse large B-cell lymphoma (DLBCL) that continues to grow despite prior treatment. MB-CART2019.1 is designed to target two proteins (CD19 and CD20) on DLBCL cells. This targeting action may help MB-CART2019.1 find cancer cells and kill them.
Participants in this study will receive fludarabine and cyclophosphamide chemotherapy before MB-CART2019.1. This prepares the body for treatment and helps MB-CART2019.1 work better to fight cancer. The treatments in this study are all given intravenously (by vein).